Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BNC210 · 5 trials · 3 indications
The SUDS is a self reported measure of the intensity of distress currently experienced by an individual. The range is 0-100, with a higher score indicating a higher level of anxiety/greater distress
The CAPS-5 is a 30-item structured interview used to diagnose PTSD and assess PTSD symptoms over the past month. Information about the frequency and intensity of each item is combined into a severity rating, and the CAPS-5 total symptom severity score is calculated by adding the severity scores for the 20 PTSD symptoms in the DSM-5. Scores range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms.
Investigator-rated PTSD symptom severity. The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.
| Arm | Type | Description |
|---|---|---|
| 225 mg BNC210 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 675 mg BNC210 | EXPERIMENTAL | - |
| BNC210 | EXPERIMENTAL | - |
| BNC210 600 mg b.i.d. | EXPERIMENTAL | Suspension administered orally for 12 weeks. |
| BNC210 300 mg b.i.d. | EXPERIMENTAL | Suspension administered orally for 12 weeks. |
| BNC210 150 mg b.i.d. | EXPERIMENTAL | Suspension administered orally for 12 weeks. |
| Placebo b.i.d. | PLACEBO_COMPARATOR | Suspension administered orally for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| 225 mg BNC210 | DRUG | 225 mg BNC210 |
| Placebo | DRUG | Placebo |
| 675 mg BNC210 | DRUG | 675 mg BNC210 |
| BNC210 | DRUG | BNC210 900 mg twice daily (b.i.d.) for 12 weeks |
Inclusion Criteria: * A current diagnosis of social anxiety disorder as defined in the DSM-5. * A Liebowitz Social Anxiety Scale total score of ≥60. * Suitable contraception use in line with protocol requirements. * Ability to swallow tablets. Exclusion Criteria: * History of bipolar disorder, sc...
BNC210 is an investigational small molecule being developed for agitation in the elderly, post-traumatic stress disorder, and social anxiety disorder. It is not approved for any indication and remains in clinical development. Neuphoria Therapeutics Inc. (ticker NEUP) is the developer.
BNC210 targets CHRNA7, also known as the alpha-7 nicotinic acetylcholine receptor. It acts as a negative allosteric modulator at this target. This mechanism is distinct from standard treatments for anxiety and agitation, which typically act on other receptor systems.
BNC210 is being developed by Neuphoria Therapeutics Inc., which trades under the ticker NEUP. The company is advancing the asset across multiple central nervous system indications, including social anxiety disorder, post-traumatic stress disorder, and agitation in the elderly.
BNC210 is in Phase 2 development overall, though one trial has been conducted at Phase 3. The program includes completed studies in social anxiety disorder, post-traumatic stress disorder, and agitation in the elderly. It is investigational and has not been approved by the FDA for any indication.
Completed trials include NCT06510504, a Phase 3 study in social anxiety disorder with 370 participants; NCT05193409, a Phase 2 study in social anxiety disorder with 151 participants; NCT04951076, a Phase 2b study in PTSD with 212 participants; and NCT03548194, a Phase 2 study in elderly agitation with 38 participants.